Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Mitchell Feinman

Rheumatology Orangeburg, SC Medical Doctor

NPI 1841479623 CMS profile 83952

1768 Village Park Dr, Orangeburg, SC 29118

Open in the dashboard

General payments

$29,610

441 records reported · program years 2019–2023

Research payments

$1,972

Paid to them · 10 records reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$794,887 paid to institutions, not to them · program years 2019–2024

Through program year 2023, Mitchell Feinman of Orangeburg, SC is reported in the CMS Open Payments database as having received $29,610 across 441 general payments and $1,972 in research payments paid to them. Separately, studies naming them as principal investigator received $794,887 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 87th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $20 1
2022 General $11,988 80
2021 General $9,876 106
2020 General $3,506 113
2020 Research $1,972 10
2019 General $4,220 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mitchell Feinman
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Mitchell Feinman were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Mitchell Feinman Rheumatology median Middle half National median
2019 $4,220 $744 $153–$2,687 $163
2020 $3,506 $462 $98–$2,027 $114
2021 $9,876 $531 $101–$2,153 $132
2022 $11,988 $627 $125–$2,303 $149
2023 $20 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Horizon Therapeutics plc $20,953 52 payments
  2. UCB Biosciences Inc. $1,796 9 payments
  3. Amgen Inc. $1,498 83 payments
  4. Pfizer Inc. $812 46 payments
  5. UCB, Inc. $665 35 payments
  6. Novartis Pharmaceuticals Corporation $563 30 payments
  7. Janssen Biotech, Inc. $543 33 payments
  8. AbbVie, Inc. $431 27 payments
  9. Lilly USA, LLC $410 26 payments
  10. E.R. Squibb & Sons, L.L.C. $339 19 payments
  11. Other $1,599 81 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Honoraria $18,890 9 payments
  2. Food and Beverage $7,984 424 payments
  3. Travel and Lodging $2,734 7 payments
  4. Education $3 1 payment
Products named General payments · program years 2019–2023
  1. KRYSTEXXA $20,936 51 payments
  2. Cimzia $665 35 payments
  3. Prolia $642 34 payments
  4. XELJANZ $577 30 payments
  5. COSENTYX $563 30 payments
  6. SIMPONI ARIA $487 30 payments
  7. Enbrel $422 23 payments
  8. INFLECTRA $417 23 payments
  9. TALTZ $410 26 payments
  10. EVENITY $401 24 payments
  11. Other $4,533 252 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. Gilead Sciences, Inc. $1,972 10 payments

Records

451 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record